'BRCAness' and its implications for platinum action in gynecologic cancer.
about
Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer PatientsCombined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patientsLoss of the N-terminal methyltransferase NRMT1 increases sensitivity to DNA damage and promotes mammary oncogenesisBRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.Regulation of therapeutic resistance in cancers by receptor tyrosine kinases.Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival.Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.The Evolution, Functions and Applications of the Breast Cancer Genes BRCA1 and BRCA2.Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer.Role of BRCA Mutations in the Modulation of Response to Platinum Therapy.Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation.Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.
P2860
Q28073673-0DE2BB9C-6CA1-41ED-8C5B-956B75BA5A4CQ33584055-C51C45B3-4A43-4EB2-986F-D004C24628F9Q34551543-7D1D6CBE-CDC7-4CF0-8171-5A42B99AF319Q35744147-F7B59D8F-5F22-4F7D-BA19-42598FEFAD45Q35828551-7E7E57A7-3AFC-427E-A139-BB3B4619B9D6Q35909611-111188DC-6A2C-45EC-9441-4E9A76E1977AQ36235684-51C8444C-2052-4729-8F5E-E0C788A955DCQ36879506-BB804471-D950-4E76-83E1-1E15917437EBQ36983535-2D011165-E868-466B-824E-8DA1D752DF74Q39262474-15D2D489-AB85-4BBC-9F6F-EEA0F69664D0Q41664074-62415FEC-7616-4F15-9D32-D29DC4F94856Q47145727-32766255-345F-45DE-A747-738AE3BB7236Q49829001-7245A12D-56BD-49BE-8797-5BA19BD003F9Q52310220-525A8952-A5E8-41BA-9EBE-4CBDFD8693B8Q52689244-673EC6F5-026F-4AB4-BE27-1AB1663DB0D5Q55377222-DE4415F2-1881-48C0-BCF1-C25F86C86B4B
P2860
'BRCAness' and its implications for platinum action in gynecologic cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
'BRCAness' and its implications for platinum action in gynecologic cancer.
@ast
'BRCAness' and its implications for platinum action in gynecologic cancer.
@en
type
label
'BRCAness' and its implications for platinum action in gynecologic cancer.
@ast
'BRCAness' and its implications for platinum action in gynecologic cancer.
@en
prefLabel
'BRCAness' and its implications for platinum action in gynecologic cancer.
@ast
'BRCAness' and its implications for platinum action in gynecologic cancer.
@en
P2860
P1433
P1476
'BRCAness' and its implications for platinum action in gynecologic cancer.
@en
P2093
Tamar Safra
P2860
P304
P407
P577
2014-02-01T00:00:00Z